the control group showed signs compatible with recurrence of focal and segmental glomerulosclerosis and Background. Outcome and the issue of recurrence of disease in systemic lupus erythematosus (SLE ) renal membranous glomerulonephritis. There was a wide variation in serum levels of antinuclear antibodies. A transplant recipients is still a matter of controversy. There is a lack of comparative studies with non-SLE wide variation in complement levels was also observed, but with a tendency towards low C4 levels. patients. The aim of this paper is to compare renal transplantation in lupus patients with a similar Conclusions. The safety of renal transplantation in SLE patients is equivalent to a matched case-control matched non-SLE group. Methods. Forty-five patients with systemic lupus eryth-group with a similar rate of recurrence of disease. ematosus subjected to 48 kidney transplants were Key words: renal transplantation; systemic lupus studied. For comparative purposes, a case-control erythematosus population was selected, matched for gender, race, type of donor, age, and time of transplantation. Patients with non-glomerulonephritis diseases were excluded.
Introduction
Results. No differences in acute episodes of rejection, causes of kidney loss or patient death were observed. Renal transplantation in systemic lupus erythematosus General as well as infectious complications were sim-(SLE ) is considered a safe procedure with a low ilar. Pregnancy rates and outcomes were similar with frequency of recurrence of primary nephropathy [1] . no deleterious effect on patients or grafts. Actuarial 1-However, outcome and the issue of recurrence of and 5-year patient survivals (97.7 and 91.1% for SLE disease in SLE renal transplant patients is still a matter and 95.4 and 87% for controls, respectively) and graft of controversy. There is a lack of comparative studies survivals (93.1 and 80.7% for SLE and 88.8 and 70.2% with non-SLE patients. This paper compares lupus for controls, respectively) were similar. Long-term renal transplant patients with a similar matched transrenal function expressed by serum creatinine was the plant population with glomerulonephritis diseases. same. No differences in immunosuppressive drug (azathioprine, prednisone, and cyclosporin) requirements
Subjects and methods
were found. Clinical SLE recurrence was suspected only once (a patient with thrombocytopenia, hypocomplementaemia with low complement levels and positive From May 1975 an immunofluorescence pattern compatible with recur-for gender, race, type of donor, time of transplantation (the rence. A fifth patient had necrotizing arteritis which nearest one in a chronological list) and age (±5 years). Patients recovered after treatment with cyclophosphamide and with diabetes, pyelonephritis, polycystic kidney disease, maliganother patient showed focal and segmental glomerulo-nant hypertension, Alport disease, metabolic and infectious sclerosis. Histology of biopsies from five patients in diseases, and all other systemic diseases were excluded.
Therefore only patients with biopsy proven glomerulonephritis or chronic renal failure due to end-stage kidney disease, very
Correspondence and offprint requests to: Dr Luiz Sergio Azevedo, likely to be due to chronic glomerulonephritis, were selected. transplant recipients were analysed. (9%) SLE patients and in three (6.6%) control cases. Mean complement measurements are shown in Figure 1 . There was a tendency toward low C4 values Low complement levels were seen with no signs of and normal C3 values. Thirty-five percent of all C4 SLE active disease. determinations were below 20 mg/dl (50.5% were
No patterns concerning antinuclear antibody measbelow 25 mg/dl ) and 16% of C3 were below 55 mg/dl. urements were observed. There was a wide variation in titres over the years of follow-up with no correlation nephropathy rather than with idiopatic nephropathy. as case-control group, in which all clinical parameters, The patient with necrotising arteritis recovered after except the presence of lupus, were similar. Even haemacyclophosphamide IV pulse therapy. We couldn't ascer-tological complications and arthralgia, which could be tain the SLE activity. The patient with focal and attributed to lupus activity, were similar. Infectious segmental glomerulosclerosis and malignant nephro-and non-infectious complications were similar as well sclerosis progressed rapidly to renal failure and to as causes of graft loss and death. The frequency of dialysis. The frequency of biopsies showing chronic arterial hypertension was the same in both groups. rejection and cyclosporin nephrotoxicity were similar. However, the frequency of post-transplant bilateral Actuarial survival data is shown in Figure 2 . There nephrectomy was greater in SLE patients. It is our was no statistical difference between SLE and control policy to perform bilateral nephrectomy in those cases for both patients and kidneys.
patients with intractable, severe hypertension, needing three or more antihypertensive drugs, mainly when polycythaemia is present. Currently we perform the Discussion captopril-stimulated renin test to detect which patients should benefit from surgery [2]. In two cases in which surgery was indicated, polycythaemia was also present. SLE is not a contraindication for renal transplantation. SLE patients had very similar patient and graft survival Signs of early malignant hypertension were seen in two transplanted kidneys. This shows that hypertension rare. Recently [17, 18] it was reported that recurrence of renal disease can be more frequent than previously may be more severe in lupus patients. Pregnancies in SLE patients had the same outcome as controls and thought. Nyberg et al. [17] found evidence of recurrence of nephropathy in five of eight biopsies perhad no deleterious influence, both for patients and their transplanted kidneys. Long-term renal function, formed for clinical indications and in two of eight performed electively. A review by Lash [18] reinforced expressed by serum creatinine, was also similar. Actuarial patient and graft survival were similar for this opinion. Recurrence of nephropathy can only be established with certainty when a biopsy of the transboth groups. As indicated by the literature [1, [3] [4] [5] [6] [7] , these survival rates are good. Few comparative studies planted kidney shows the same histological pattern as the native kidney. However, we cannot disregard cases with a non-SLE population are published. Grimbert et al. [7] compared 53 patients (60 transplants) with in which biopsy of the native kidney is lacking and the clinical picture and histology of the transplanted kidney 106 matched controls and found similar survival rates both for grafts and patients. In a multicentre database are suggestive of recurrence. Although de novo glomerulonephritis may be found in patients with known analysis of 138 SLE patients compared with a cohort of 6125 non-SLE cyclosporin-treated recipients of non-glomerular disease, we decided to consider all cases in which clinical and histological pictures were cadaver kidneys, Krishnan et al.
[8] reported a slightly worse survival for SLE grafts (71 vs 78%). However, compatible with recurrence as probable recurrence cases. Most patients, in the SLE and case-control there was no difference when the data were stratified for several variables. They concluded that lupus neph-groups had no native kidney biopsy. As this occurred at the same rate, there was no bias. Renal biopsies ritis was not causally related to allograft survival. Lochhead et al. [9] in a comparative study of 80 were reanalysed by a blinded observer ( Table 5 ). The frequency of histological picture compatible with recurtransplants in SLE patients with a non-diabetic transplant population (n=1966) found a similar survival rence were very similar in both groups. Chronic glomerulonephritis patients were selected for case-control rate, although poorer survival for cadaver grafts in a lupus population in the era of cyclosporin was group, and therefore potentially prone to have nephropathy recurrence. Glomerular disease recurs in SLE observed. Two case-control studies have been published [10, 11] . In contrast with our study, the control patients with a similar frequency as other glomerular disease patients. population included patients with non-glomerular disease, such as pyelonephritis, polycystic disease, or
In our lupus population only one patient had evidence of clinical recurrence: a patient with thrombocytosystemic diseases. In one of them (32 SLE patients), Bumgardner et al. [10] showed that actuarial patient penia, antiplatelet antibodies, and low levels of complement. and graft survival at 1, 5 and 10 years was the same for SLE and case-control groups for cadaver and living Complement levels varied widely, but with a tendency to stay at the lower limits. No differences were donors. On the other hand, Nyberg et al.
[11] found a worse 1-year graft survival in 31 SLE patients (36 vs seen in the doses of the three main drugs used: azathioprine, prednisone and cyclosporin. SLE patients tended 82% for azathioprine-and 59 vs 85% for cyclosporintreated patients).
to have a lower graft rejection rate which was not significant. In contrast, Lochhead et al. [9] found an All systemic disease can, theoretically, recur in the transplant patient. This has been reported in the literat-increased risk for acute and chronic graft rejection in SLE patients. However, their comparison was with the ure for lupus patients, both for systemic disease and for nephropathy [1, 7, [12] [13] [14] [15] [16] but it is considered to be entire non-diabetic population. Nyberg et al. [11] 5. Hariharan S, Schroder TJ, Carey MA, First MR. Renal transfound that most graft failure was due to rejection with plantation in patients with systemic lupus erythematosus. Clin a high proportion of vascular rejection. Bumgardner 
